Dr Clifford Goodman Discusses How Healthcare Should Address Social Determinants of Health
July 20th 2018If we’re truly serious about being outcomes oriented in healthcare, we can’t come near accomplishing what we’d like to accomplish without direct intervention with regard to social determinants, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.
Read More
Sally Okun on How Informed Patients Feel When Starting Treatment After a New Diagnosis
July 9th 2018The most common question patients ask when they start a new treatment after a new diagnosis is "what will this do to me?" explained Sally Okun, RN, MMHS, vice president, Policy and Ethics, PatientsLikeMe.
Read More
Dr Clifford Goodman on Progress With the Move to Value-Based Payments
July 9th 2018Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.
Read More
Dr Adrian F. Hernandez: Mapping Human Health Through Project Baseline
July 3rd 2018The purpose of Project Baseline is to map human health so we can convert from a reactive healthcare system to a proactive healthcare system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine
Read More
Dr Harlan Krumholz: How Healthcare Can Better Implement New Technologies
June 29th 2018We need to collaborate and test these innovations in controlled circumstances so that we can evaluate their effect and understand what needs to be iterated to continue to improve them, explained Harlan Krumholz, MD, SM, the Harold H. Hines Jr professor, Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.
Read More
Dr Ejim Mark: Challenges With and Protecting the Increasing Amount of Health Data
June 27th 2018Not all health data is collected in a similar manner, so analyzing such data can be challenging for researchers, explained Ejim E. Mark, MD, MPH, MBA, CEO and founder of Access Healthcare Foundation.
Read More
Dr Adrian F. Hernandez on the Future of Real-World Evidence
June 20th 2018Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine discusses how technology can be used to improve the way we gather and use real-world evidence, the promise that real-world evidence holds, and how he thinks real-world evidence will be used in the coming years.
Read More
Dr Harlan Krumholz on Using New Technologies, Data Generation to Prevent or Address Epidemics
June 18th 2018If we’ve got data moving, and if we’re analyzing it in smart ways in real time, we should be able to detect problems within our healthcare system much more rapidly than we have been able to in the past, explained Harlan Krumholz, MD, SM, the Harold H. Hines Jr professor, Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.
Read More
Sally Okun: Using Digital Health Improvements to Include the Patient Voice in Healthcare
June 14th 2018Sally Okun, RN, MMHS, vice president, Policy and Ethics, PatientsLikeMe, discusses how digital health improvements help include the patient voice in healthcare and how the United States' use of real-world evidence compares with how it's used in other countries.
Read More
Valuation Challenges and Ethical Implications of Cures
May 24th 2018As new treatments come to market that have a substantial impact on diseases, or even cure them, the healthcare system is facing the challenge of how to value these treatments. A panel of experts highlighted what evidence there needs to be, methods of valuing therapies, and the ethical implications of having cures.
Read More
Value Assessments in the Age of Personalized Medicine May Require a Cultural Shift, Panel Says
May 23rd 2018On the closing day of the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, in Baltimore, Maryland, stakeholders gathered to grapple with the role of value assessments in a healthcare landscape that is increasingly focused on the use of precision medicine in treating disease.
Read More
Dr Steven Pearson Highlights the Challenge of Evaluating New Interventions That Cure Diseases
May 23rd 2018In order to start evaluating the economics of new cures, the scope of the evaluation needs to be as broad as possible and be able to wrestle with uncertainty, said Steven Pearson, MD, MSc, founder and president of the Institute for Clinical and Economic Review.
Read More
Panelists Give Payer, Patient, and Economist Perspectives on High-Cost Drugs for Rare Diseases
May 23rd 2018Advances in medicine have produced breakthroughs in the treatment of a number of rare diseases, but these advances often come at a high cost. A multi-stakeholder panel at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, in Baltimore, Maryland, addressed the question of how to define value in the always evolving and ever more expensive treatment landscape.
Read More
Dr Adrian Hernandez Highlights the Use of Real-World Evidence and Current Barriers
May 23rd 2018In some ways, the United States is progressive in its use of real-world evidence, but there are still areas where other countries do a better job of incorporating such evidence into the health system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine.
Read More
Personalizing the Digital Data Revolution in Healthcare
May 22nd 2018How valuable are digital data collection tools in healthcare and what do they mean to the patient? Are they helpful or is this revolution merely a hype? These were some of the discussions during the plenary session on the second day of the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting.
Read More
Posters presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, highlighted healthcare costs for patients with treatment-resistant depression, off-label drug use in children with depressive disorder, and incidence of depression in patients diagnosed with late-stage cancer.
Read More
Dr Clifford Goodman Discusses the Challenge of Valuing New, Expensive Therapies for Rare Diseases
May 22nd 2018Legislation, advancing science, and more sophisticated patient advocacy has led to a proliferation of new therapies to treat rare diseases, and society has begun to indicate a willingness to pay for these more expensive therapies, said Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.
Read More
Sally Okun: It's Time to Empower the Health Data Being Collected
May 21st 2018There is a monumental amount of data being collected in healthcare, but now it’s time to make sure that data is empowered so it can start being used to answer questions and improve decision making, said Sally Okun, RN, MMHS, vice president, Policy and Ethics, PatientsLikeMe.
Read More
Transforming Healthcare: Boosting Real-World Evidence With Digital Health
May 21st 2018At the first plenary session at the ISPOR 2018 conference, May 19-23 in Baltimore, Maryland, panelists updated the audience on how digital progress can influence real-world evidence to allow near real-time data analysis and inclusion of specific patient information, lowering cost and providing higher quality care downstream.
Read More
Value Assessments Are Just One Tool in the Decision-Maker's Toolkit, Panel Says
May 21st 2018In a Monday panel convened at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, stakeholders grappled with the role that value assessments play—or should play—in US private payer coverage and formulary decisions.
Read More
Dr Harlan Krumholz Outlines the Impact of New Technology and Innovations on Healthcare Delivery
May 21st 2018Innovations are transforming healthcare, but these innovations have to align with business models and they still have to be validated before they can improve care delivery, explained Harlan Krumholz, MD, SM, Harold H. Hines Jr professor of Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.
Read More
Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
September 8th 2017Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow, discusses what needs to be included in the next generation of value assessment frameworks in order to best identify value that is representative of all patient preferences.
Read More
Dr Patricia Danzon: Learning From European Health Systems
August 30th 2017The United States can benefit from taking and adapting certain elements of European countries’ systems and methods of assessing value, says Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
Read More
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
August 23rd 2017A one-size-fits-all approach to value is impossible in the US healthcare system, but a pluralistic approach is extremely complex to implement, says Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.
Read More
Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices
August 16th 2017A combination of different countries’ health systems can set an example for the United States to follow in efforts to restrain the ongoing increases in drug prices, explains Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
Read More
Dr Ilene Hollin Outlines Differing Definitions of Value
August 9th 2017Patients, payers, and providers all view value in different ways, and they all need to be taken into account in value frameworks, said Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.
Read More
Dr Patricia Danzon: Cost Effective Doesn't Mean Affordable
August 3rd 2017There are differences between cost effectiveness and affordability that people don't always understand. A drug may be cost effective but still not fall within the budget, explained Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
Read More
Dr Michael Sherman on Performance-Based Risk-Sharing Agreements
July 28th 2017Michael Sherman, MD, chief medical officer at Harvard Pilgrim Health Care, discusses the challenges of moving towards performance-based risk-sharing agreements and where they would work best for certain treatments.
Read More